Filing Overview
Pliant Therapeutics, Inc. filed a Form 8-K reporting an amendment and restatement of its bylaws. The relevant board approval occurred on December 15, 2020; the filing was signed on December 21, 2020. Pliant is a Delaware corporation whose common stock trades on Nasdaq under the symbol PLRX.
Business Context and Reporting Period
This filing is a corporate-governance disclosure under Item 5.03 and does not report quarterly or annual operating results. It covers the bylaw amendment approved on December 15, 2020.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other financial performance metrics.
Material Changes
- The board approved amended and restated bylaws.
- The amendment designates the federal district courts of the United States as the sole and exclusive forum for actions asserting claims under the Securities Act of 1933, unless the company consents in writing to an alternative forum.
Management Commentary, Risks, and Unusual Items
The filing provides no management outlook or operating commentary. The exclusive-forum provision may affect where investors can bring Securities Act claims and could increase the practical significance of the company’s consent in any alternative-forum proceeding.
Important Facts to Verify
- Review Exhibit 3.1, the complete amended and restated bylaws dated December 15, 2020.
- Confirm the scope and exceptions of the federal exclusive-forum provision.
- Review subsequent filings for any amendments, litigation, or disclosure regarding enforceability of the provision.